Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Stock Information for Cogent Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cogent Biosciences Inc.

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants
Cogent Biosciences Announces Proposed Public Offering of Common Stock
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
Cogent Biosciences Announces Annual Meeting of Stockholders
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.